share placement

Last one was undersubscribed with - options expiring Aug 2011, exercise 15c.

Maybe management have learnt something.

This one oversubscribed with options expiring 2016, exercise 9c.

Higher price for shares but a much, much better deal on options. If they had offered that last time I wonder if the uptake would have been substantially more ?

Anyway, these bucks should see them funded for quite awhile, along with the income they are deriving from the research.

I will be interested to see the figure from Roche - next quarterly perhaps ?

Q. where will these new shares be traded - ASX, Frankfurt ?
(did we get a NASDAQ listing ? (-:)
I never did quite understand where shares came from to trade on the Frankfurt exchange.